APO(a) variants and lipoprotein(a) in men with or without myocardial infarction

被引:9
作者
Chimienti, G
Lamanuzzi, BL
Nardulli, M
Colacicco, AM
Capurso, A
La Gioia, R
Scrutino, D
Pepe, G
机构
[1] Univ Bari, Dept Biochem & Mol Biol, CNR, CSMME, I-70126 Bari, Italy
[2] Univ Bari, Geriatr Chair, I-70126 Bari, Italy
[3] IRCCS S Maugeri, Cardiol Unit, Cassano Bari, Italy
关键词
cardiovascular diseases; myocardial infarction; Lp(a); apo(a) gene variants; genetic determinism; multifactorial disease;
D O I
10.1006/exmp.2002.2445
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The lipoprotein Lp(a) with high plasma concentration is an independent genetic determinant for cardiovascular diseases. It was investigated as a quantitative factor of risk for myocardial infarction. A total Of 345 Italian subjects, 127 Cases and 218 Controls, were studied. Lipids and lipoproteins were compared. Cases had atherogenic traits, such as lower HDL cholesterol and higher triglycerides than Controls. In particular, they had Lp(a) concentrations over the risk threshold, (median, 27 mg/dl in Cases vs 17 mg/dl in Controls; P = 0.0075, Mann-Whitney test) which confirmed the association of this parameter with the disease. Two main functional variants of the apo(a) gene, KringleIV and penta-nucleotide repeat, (PNR) were analyzed. Allele and genotype frequency distributions differed between Cases and Controls. Lp(a) concentrations differed according to PNR genotypes in Controls: subjects having alleles >8 showed lower Lp(a). This was not found in Cases. They had a higher prevalence of the smaller KringleIV alleles, the high Lp(a)-expressing ones. In Cases, genotypes consisting of two small KringleIV alleles were prevalently associated to PNR 8/9 and 8/10, thus preventing Lp(a) lowering. The putative apo(a) enhancer within LINE1 in the apo(a)-plasminogen intergenic region was investigated for functional polymorphisms. No variants that could be associated to the Lp(a) variability were found. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:28 / 34
页数:7
相关论文
共 30 条
[1]   Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study [J].
Brazier, L ;
Tiret, L ;
Luc, G ;
Arveiler, D ;
Ruidavets, JB ;
Evans, A ;
Chapman, J ;
Cambien, F ;
Thillet, J .
ATHEROSCLEROSIS, 1999, 144 (02) :323-333
[2]   High risk strategies for atherosclerosis [J].
Cullen, P ;
Assmann, G .
CLINICA CHIMICA ACTA, 1999, 286 (1-2) :31-45
[3]   Lipoprotein Lp(a) and atherothrombotic disease [J].
de la Peña-Díaz, A ;
Izaguirre-Avila, R ;
Anglés-Cano, E .
ARCHIVES OF MEDICAL RESEARCH, 2000, 31 (04) :353-359
[4]  
Gaw Allan, 1994, Current Opinion in Lipidology, V5, P149, DOI 10.1097/00041433-199404000-00012
[5]   LIPOPROTEIN(A) AND CORONARY HEART-DISEASE RISK - A NESTED CASE-CONTROL STUDY OF THE HELSINKI HEART-STUDY PARTICIPANTS [J].
JAUHIAINEN, M ;
KOSKINEN, P ;
EHNHOLM, C ;
FRICK, MH ;
MANTTARI, M ;
MANNINEN, V ;
HUTTUNEN, JK .
ATHEROSCLEROSIS, 1991, 89 (01) :59-67
[6]   EFFECTS OF AGE, SEX, AND MENOPAUSAL STATUS ON PLASMA LIPOPROTEIN(A) LEVELS - THE FRAMINGHAM OFFSPRING STUDY [J].
JENNER, JL ;
ORDOVAS, JM ;
LAMONFAVA, S ;
SCHAEFER, MM ;
WILSON, PWF ;
CASTELLI, WP ;
SCHAEFER, EJ .
CIRCULATION, 1993, 87 (04) :1135-1141
[7]   Aspirin reduces apolipoprotein(a) (Apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription [J].
Kagawa, A ;
Azuma, H ;
Akaike, M ;
Kanagawa, Y ;
Matsumoto, T .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (48) :34111-34115
[8]   Presence of two plasminogen alleles in normal populations [J].
Kida, M ;
Kawabata, MH ;
Yamazaki, T ;
Ichinose, A .
THROMBOSIS AND HAEMOSTASIS, 1998, 79 (01) :150-154
[9]  
KRAFT HG, 1992, HUM GENET, V90, P220
[10]  
KUNZ B, 2001, EUR J HUM GENET, V19, P369